Recombinant Human CXC-Chemokine Receptor-4 in Melanophores Are Linked to Gi Protein: Seven Transmembrane Coreceptors for Human Immunodeficiency Virus Entry into Cells
- Wen-Ji Chen1,
- Channa Jayawickreme2,
- Chris Watson2,
- Larry Wolfe2,
- William Holmes1,
- Robert Ferris3,
- Susan Armour1,
- Walter Dallas1,
- Grace Chen2,
- Larry Boone3,
- Michael Luther1 and
- Terry Kenakin2
- Departments of 1Molecular Sciences (W.-J.C., W.H., S.A.,W.D., M.L.),2Receptor Biochemistry (C.J., C.W., L.W., G.C., T.K.), and 3Virology (R.F., L.B.), Glaxo Wellcome Research and Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709
Abstract
This article describes the transient expression of the CXC chemokine receptor-4 in Xenopuslaevis melanophores and the resulting functional assay for the endogenous ligand for this receptor stromal cell-derived factor (SDF)-1α. Specifically, it will be shown that SDF-1α produces increased light transmittance in transfected cells that is consistent with the activation of Gi protein. This stimulus pathway is further implicated by the abolition of this response after pretreatment of the cells with pertussis toxin, a known method for the inactivation of Giprotein. The fact that SDF-1α does not produce responses in nontransfected cells and that treatment of the cells with 12G5, an antibody specific for the CXC chemokine receptor-4, eliminates this response indicates that this ligand produces responses by activation of this receptor in these cells. The possible relevance to human immunodeficiency virus (HIV) entry into cells was explored by observing the effects of SDF-1α on HIV-mediated cell fusion. It was found that SDF-1α blocked cell-to-cell fusion (as has been previously reported) at concentrations 1200-fold greater than those required to produce Gi protein mediated responses. The implications of the functional assay to screening for new drugs to block HIV-mediated fusion is discussed.
Footnotes
-
Send reprint requests to: Terry Kenakin, Ph.D., Department of Receptor Biochemistry, Glaxo Wellcome Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709.
- Abbreviations:
- HIV-1
- human immunodeficiency virus type 1
- CXCRx
- CXC chemokine receptor, where xis the receptor number
- SDF
- stromal cell-derived factor
- BSA
- bovine serum albumin
- PCR
- polymerase chain reaction
- HEPES
- 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
- SDS
- sodium dodecyl sulfate
- ED50
- dose effective on 50% of the population
-
- Received August 29, 1997.
- Accepted October 29, 1997.
- The American Society for Pharmacology and Experimental Therapeutics



